Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins

Abstract Eight patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemotherapy, a supralethal dose of total-body irradiation, and a bone marrow transplant from a normal identical twin. Seven patients experienced complete remission. Four of the seven patients (two with diffuse poorly differentiated lymphocytic lymphoma, one with composite lymphoma, and one with diffuse moderately well differentiated lymphocytic lymphoma) remain in complete unmaintained remission 12–126 mo from transplantation. One patient relapsed after 10 mo but was retreated and is alive in unmaintained complete remission 73 mo from transplantation. One patient died of Pseudomonas pneumonia while in complete remission and one patient relapsed and died of progressive lymphoma. These results demonstrate that intensive chemoradiotherapy and twin marrow transplantation can induce frequent and enduring remissions in patients with disseminated non-Hodgkin's lymphoma who have failed conventional therapy.

Download Full-text

Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins

Blood ◽

10.1182/blood.v58.3.509.bloodjournal583509 ◽

1981 ◽

Vol 58 (3) ◽

pp. 509-513

Author(s):

FR Appelbaum ◽

A Fefer ◽

MA Cheever ◽

CD Buckner ◽

PD Greenberg ◽

...

Keyword(s):

Complete Remission ◽

Marrow Transplantation ◽

Hodgkin’S Lymphoma ◽

High Dose Chemotherapy ◽

Marrow Transplant ◽

Hodgkin's Lymphoma ◽

High Dose ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Well Differentiated

Eight patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemotherapy, a supralethal dose of total-body irradiation, and a bone marrow transplant from a normal identical twin. Seven patients experienced complete remission. Four of the seven patients (two with diffuse poorly differentiated lymphocytic lymphoma, one with composite lymphoma, and one with diffuse moderately well differentiated lymphocytic lymphoma) remain in complete unmaintained remission 12–126 mo from transplantation. One patient relapsed after 10 mo but was retreated and is alive in unmaintained complete remission 73 mo from transplantation. One patient died of Pseudomonas pneumonia while in complete remission and one patient relapsed and died of progressive lymphoma. These results demonstrate that intensive chemoradiotherapy and twin marrow transplantation can induce frequent and enduring remissions in patients with disseminated non-Hodgkin's lymphoma who have failed conventional therapy.

Download Full-text

Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique

Blood ◽

10.1182/blood.v81.8.2003.2003 ◽

1993 ◽

Vol 81 (8) ◽

pp. 2003-2006 ◽

Cited By ~ 45

Author(s):

T Philip ◽

O Hartmann ◽

R Pinkerton ◽

JM Zucker ◽

JC Gentet ◽

...

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

High Dose Chemotherapy ◽

Marrow Transplant ◽

Hodgkin's Lymphoma ◽

High Dose ◽

First Line Therapy ◽

Line Therapy ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Abstract The very high cure rate in advanced B-cell non-Hodgkin's lymphoma in children using intensive multiagent therapy has been previously reported by the French Societe Francaise d'Oncologie Pediatrique lymphoma Malin B type (LMB) group. To address the issue of salvageability in an unselected group of patients who had all received the same front-line therapy, the outcome of relapses following the LMB 84 (216 patients) protocol have been reviewed. Fourteen percent of patients achieving complete remission (CR) relapsed, ie, 27 of 195. Relapse sites comprised the central nervous system (CNS) alone (6 cases), lung or mediastinum (2 cases), abdomen (8 cases), head and neck (2 cases), or multifocal (9 cases). There were three early deaths due to disease. Twenty-four patients received rescue chemotherapy regimens and 15 were treated with high-dose chemotherapy and bone marrow rescue (1 allogeneic). Of these, 9 were in second CR, 4 in second partial remission, and 2 treated during progressive disease. One died in CR from treatment-related toxicity. Ten relapsed postbone marrow transplant and 4 are alive disease free and probably cured. Two of the long-term survivors had some delay during initial chemotherapy due to toxicity and two were isolated CNS relapses. Twelve of 27 patients did not proceed to megatherapy (12 of 12 died).

Download Full-text

Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique

Blood ◽

10.1182/blood.v81.8.2003.bloodjournal8182003 ◽

1993 ◽

Vol 81 (8) ◽

pp. 2003-2006

Author(s):

T Philip ◽

O Hartmann ◽

R Pinkerton ◽

JM Zucker ◽

JC Gentet ◽

...

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

High Dose Chemotherapy ◽

Marrow Transplant ◽

Hodgkin's Lymphoma ◽

High Dose ◽

First Line Therapy ◽

Line Therapy ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

The very high cure rate in advanced B-cell non-Hodgkin's lymphoma in children using intensive multiagent therapy has been previously reported by the French Societe Francaise d'Oncologie Pediatrique lymphoma Malin B type (LMB) group. To address the issue of salvageability in an unselected group of patients who had all received the same front-line therapy, the outcome of relapses following the LMB 84 (216 patients) protocol have been reviewed. Fourteen percent of patients achieving complete remission (CR) relapsed, ie, 27 of 195. Relapse sites comprised the central nervous system (CNS) alone (6 cases), lung or mediastinum (2 cases), abdomen (8 cases), head and neck (2 cases), or multifocal (9 cases). There were three early deaths due to disease. Twenty-four patients received rescue chemotherapy regimens and 15 were treated with high-dose chemotherapy and bone marrow rescue (1 allogeneic). Of these, 9 were in second CR, 4 in second partial remission, and 2 treated during progressive disease. One died in CR from treatment-related toxicity. Ten relapsed postbone marrow transplant and 4 are alive disease free and probably cured. Two of the long-term survivors had some delay during initial chemotherapy due to toxicity and two were isolated CNS relapses. Twelve of 27 patients did not proceed to megatherapy (12 of 12 died).

Download Full-text